Bank of New York Mellon’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
Other funds holding EBS
OHA
Bank of New York Mellon's EBS Position: Q2 2026 in Review
Bank of New York Mellon increased its Emergent Biosolutions (EBS) stake by 2.1% in Q2 2026, buying an estimated $38.6K and bringing the position to 219,661 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2997.
Bank of New York Mellon first reported a position in EBS in Q2 2013 and has held it in 52 quarters since. The position peaked at $91.2M in Q2 2015. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.
- Bank of New York Mellon held 219,661 shares of Emergent Biosolutions worth $1.84M as of Q2 2026.
- Bank of New York Mellon bought 4,618 Emergent Biosolutions shares in Q2 2026, an estimated $38.6K.
- Emergent Biosolutions made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2997 holding.
- Bank of New York Mellon first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 52 quarters since.
- Bank of New York Mellon's Emergent Biosolutions position peaked at $91.2M in Q2 2015.
- 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.